157 related articles for article (PubMed ID: 38633111)
1. Emicizumab for acquired hemophilia A: Report of two cases and dosing strategies.
Ahmed F; Kasianchyk M; Moreno A; Chang S; Maharaj S
EJHaem; 2024 Apr; 5(2):387-391. PubMed ID: 38633111
[TBL] [Abstract][Full Text] [Related]
2. Utilization of emicizumab in acquired hemophilia A: A case report.
Yates SG; Webb CB; Sarode R; Ibrahim IF; Shen YP
Transfus Apher Sci; 2022 Dec; 61(6):103457. PubMed ID: 35643753
[TBL] [Abstract][Full Text] [Related]
3. Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group.
Pfrepper C; Klamroth R; Oldenburg J; Holstein K; Eichler H; Hart C; Moehnle P; Schilling K; Trautmann-Grill K; Alrifai M; Ay C; Miesbach W; Knoebl P; Tiede A
Hamostaseologie; 2023 Dec; ():. PubMed ID: 38049124
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab as first-line therapy in acquired hemophilia A.
Iarossi M; Hermans C
Res Pract Thromb Haemost; 2024 May; 8(4):102438. PubMed ID: 38953052
[TBL] [Abstract][Full Text] [Related]
5. Emicizumab for the treatment of acquired hemophilia A.
Knoebl P; Thaler J; Jilma P; Quehenberger P; Gleixner K; Sperr WR
Blood; 2021 Jan; 137(3):410-419. PubMed ID: 32766881
[TBL] [Abstract][Full Text] [Related]
6. Advances in Acquired Hemophilia A.
Poston JN; Kruse-Jarres R
Transfus Med Rev; 2022 Oct; 36(4):215-219. PubMed ID: 36280447
[TBL] [Abstract][Full Text] [Related]
7. An anti-factor IXa/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A.
Takeyama M; Nogami K; Matsumoto T; Noguchi-Sasaki M; Kitazawa T; Shima M
J Thromb Haemost; 2020 Apr; 18(4):825-833. PubMed ID: 31984625
[TBL] [Abstract][Full Text] [Related]
8. Emicizumab Use in Treatment of Acquired Hemophilia A: A Case Report.
Al-Banaa K; Alhillan A; Hawa F; Mahmood R; Zaki A; El Abdallah M; Zimmerman J; Musa F
Am J Case Rep; 2019 Jul; 20():1046-1048. PubMed ID: 31318850
[TBL] [Abstract][Full Text] [Related]
9. Should emicizumab be used in patients with acquired hemophilia A?
Tiede A; Kemkes-Matthes B; Knöbl P
J Thromb Haemost; 2021 Mar; 19(3):637-644. PubMed ID: 33306259
[TBL] [Abstract][Full Text] [Related]
10. Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A.
Hart C; Klamroth R; Sachs UJ; Greil R; Knoebl P; Oldenburg J; Miesbach W; Pfrepper C; Trautmann-Grill K; Pekrul I; Holstein K; Eichler H; Weigt C; Schipp D; Werwitzke S; Tiede A
J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38936699
[TBL] [Abstract][Full Text] [Related]
11. Hemostatic therapy as a management strategy for acquired hemophilia: what does the future hold?
Franchini M; Schiavulli M; Liumbruno GM
Expert Rev Hematol; 2021 Mar; 14(3):263-270. PubMed ID: 33655810
[No Abstract] [Full Text] [Related]
12. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding.
Pasca S; Zanon E; Mannucci PM; Peyvandi F
Blood Transfus; 2023 Nov; 21(6):549-556. PubMed ID: 36795341
[TBL] [Abstract][Full Text] [Related]
13. Innovative Therapies for Acquired Hemophilia A.
Franchini M; Focosi D
Semin Thromb Hemost; 2024 Feb; ():. PubMed ID: 38395066
[TBL] [Abstract][Full Text] [Related]
14. Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment.
Zanon E
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766524
[TBL] [Abstract][Full Text] [Related]
15. Emicizumab for the treatment of acquired hemophilia A: Retrospective review of a single-institution experience.
Chen EC; Gibson W; Temoczko P; Connell NT; Handin R; Parnes AD
Haemophilia; 2023 Jan; 29(1):84-89. PubMed ID: 36163651
[TBL] [Abstract][Full Text] [Related]
16. Review of Potential Barriers to Effective Hemostatic Management of Acquired Hemophilia A by Non-Hemophilia Experts in the United States.
Sharathkumar A; Mokdad AG
Cureus; 2023 Jan; 15(1):e33927. PubMed ID: 36819387
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Emicizumab in Acquired Factor VIII Deficiency.
Hess KJ; Patel P; Joshi AM; Kotkiewicz A
Am J Case Rep; 2020 May; 21():e922326. PubMed ID: 32376817
[TBL] [Abstract][Full Text] [Related]
18. Acquired Hemophilia A: Bleeding Pattern and Hemostatic Therapeutic Strategies.
Marino R
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893457
[TBL] [Abstract][Full Text] [Related]
19. The role of emicizumab in acquired hemophilia A.
Poston J; Kruse-Jarres R
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):24-30. PubMed ID: 38066880
[TBL] [Abstract][Full Text] [Related]
20. Emicizumab in acquired haemophilia A: about two clinical cases and literature review.
Hansenne A; Hermans C
Ther Adv Hematol; 2021; 12():20406207211038193. PubMed ID: 34471508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
